Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-initiated Trial Evaluating the Efficacy and Safety of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of Relapsed / Refractory(r/r) Multiple Myeloma(MM)

NCT05739188 is registered in ClinicalTrials.gov with 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China as lead sponsor.

NCT NCT05739188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05739188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-initiated Trial Evaluating the Efficacy and Safety of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of Relapsed / Refractory(r/r) Multiple Myeloma(MM)
Lead sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 7, 2023
Completion date
December 31, 2025
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse, multiple myeloma, refractory